Distinct gut microbiota profiles may characterize amyloid beta pathology and mild cognitive impairment

Konstantinos Rouskas,Eirini Mamalaki,Eva Ntanasi,Marianna Pantoura,Maria Anezaki,Christina Emmanouil,Nil Novau-Ferré,Mònica Bulló,Antigone S Dimas,Christopher Papandreou,Mary Yannakoulia,Anagnostis Argiriou,Nikolaos Scarmeas

DOI: https://doi.org/10.1101/2024.05.01.24306673

2024-05-03

Abstract:Gut microbiome composition has been associated with early preclinical Alzheimer’s disease (AD), as reflected by cerebrospinal fluid (CSF) amyloid beta pathology, and with mild cognitive impairment (MCI). However, the presence of distinct microbiota across different disease stages has not been fully characterized. We profiled gut microbiota in 50 nondemented individuals by 16S ribosomal RNA sequencing and taxonomic profiles were compared between amyloid-based (amyloid-normal vs. amyloid-pathology) and clinically- based (cognitively normal vs. MCI) diagnosis groups using linear models (adjusted for sex, age and diet). Elastic net regression model was used to assess the discriminative performance of microbiota for amyloid-pathology and MCI. Microbial diversity measures did not differ across groups. We identified specific genera associated with amyloid-pathology and MCI such as and , mostly linked to inflammation. Distinct genera were found to be unique to amyloid-pathology and MCI. Microbiota was shown to have a fairly good discriminative performance. Overall, we suggest the presence of distinct microbiota in early preclinical stage of AD and MCI, which needs to be further explored.

Neurology

What problem does this paper attempt to address?

This paper investigates the differences in the characteristics of gut microbiota between the asymptomatic stage of early Alzheimer's disease (AD) reflected by beta-amyloid pathology in the cerebrospinal fluid and mild cognitive impairment (MCI). The study analyzed the gut microbiota of 50 non-demented individuals using 16S rRNA sequencing and compared the differences between groups based on beta-amyloid pathology and clinical diagnosis (cognitively normal vs MCI).

The study found that, although there was no significant difference in microbial diversity, specific genera such as Oxalobacter, Marvinbryantia, and Escherichia-Shigella were associated with beta-amyloid pathology and MCI, particularly in relation to inflammatory processes. In addition, unique patterns of different genera were identified in relation to beta-amyloid pathology and MCI. The microbial community showed good discriminative ability between beta-amyloid pathology and MCI.

The paper highlights the potential unique patterns of gut microbiota in the early stages of AD, which requires further research as potential early diagnostic biomarkers and therapeutic targets. By establishing predictive models, the researchers found that certain microbiota could differentiate beta-amyloid pathology from MCI status, and some microbiota levels were correlated with AD biomarkers.

In conclusion, this study reveals the role of gut microbiota in the early progression of Alzheimer's disease, providing a new perspective for understanding the disease process and developing new diagnostic and treatment methods.